Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note

Doximity (DOCS) closed the most recent trading day at $25.81, moving -2.2% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.45%. Meanwhile, the Dow lost 0.63%, and the Nasdaq, a tech-heavy index, lost 0.78%.

Coming into today, shares of the medical social networking site had gained 7.63% in the past month. In that same time, the Medical sector gained 0.57%, while the S&P 500 lost 1.99%.

Analysts and investors alike will be keeping a close eye on the performance of Doximity in its upcoming earnings disclosure. The company is predicted to post an EPS of $0.34, indicating a 24.44% decline compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $170.66 million, up 1.27% from the prior-year quarter.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $1.33 per share and a revenue of $675.74 million, signifying shifts of -12.5% and +4.79%, respectively, from the last year.

Investors should also take note of any recent adjustments to analyst estimates for Doximity. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. As of now, Doximity holds a Zacks Rank of #3 (Hold).

Investors should also note Doximity's current valuation metrics, including its Forward P/E ratio of 19.78. This indicates a discount in contrast to its industry's Forward P/E of 28.27.

Investors should also note that DOCS has a PEG ratio of 11.5 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Medical Info Systems industry was having an average PEG ratio of 3.24.

The Medical Info Systems industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 85, placing it within the top 35% of over 250 industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Doximity, Inc. (DOCS) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Zacks
Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.
More articles by this source

Tags

Stocks Mentioned

Latest Articles

Data is currently not available